GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Navamedic ASA (FRA:N1A) » Definitions » Debt-to-EBITDA

Navamedic ASA (FRA:N1A) Debt-to-EBITDA : 4.45 (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Navamedic ASA Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Navamedic ASA's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €6.12 Mil. Navamedic ASA's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €8.98 Mil. Navamedic ASA's annualized EBITDA for the quarter that ended in Dec. 2023 was €3.39 Mil. Navamedic ASA's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 4.45.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Navamedic ASA's Debt-to-EBITDA or its related term are showing as below:

FRA:N1A' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -4.36   Med: 4.65   Max: 13.06
Current: 5.69

During the past 13 years, the highest Debt-to-EBITDA Ratio of Navamedic ASA was 13.06. The lowest was -4.36. And the median was 4.65.

FRA:N1A's Debt-to-EBITDA is ranked worse than
82.67% of 75 companies
in the Medical Distribution industry
Industry Median: 2 vs FRA:N1A: 5.69

Navamedic ASA Debt-to-EBITDA Historical Data

The historical data trend for Navamedic ASA's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Navamedic ASA Debt-to-EBITDA Chart

Navamedic ASA Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.36 -4.17 5.87 1.25 5.69

Navamedic ASA Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.74 2.11 0.93 6.08 4.45

Competitive Comparison of Navamedic ASA's Debt-to-EBITDA

For the Medical Distribution subindustry, Navamedic ASA's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Navamedic ASA's Debt-to-EBITDA Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Navamedic ASA's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Navamedic ASA's Debt-to-EBITDA falls into.



Navamedic ASA Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Navamedic ASA's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(6.118 + 8.984) / 2.654
=5.69

Navamedic ASA's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(6.118 + 8.984) / 3.394
=4.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.


Navamedic ASA  (FRA:N1A) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Navamedic ASA Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Navamedic ASA's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Navamedic ASA (FRA:N1A) Business Description

Traded in Other Exchanges
Address
Henrik Ibsensgate 100, Solli Plass, Lysaker, NOR, N-0255
Navamedic ASA is a pharmaceutical company that operates in a single segment, which is marketing, selling, and distributing pharmaceuticals and medical nutrition products to hospitals, pharmacies, and patients, bought from product suppliers and manufacturers in Europe and other places. Its product categories include Medical nutrition, Consumer health, Branded generics, and Specialty pharma.

Navamedic ASA (FRA:N1A) Headlines

No Headlines